Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01969370 · ClinicalTrials.gov registry record · NA

NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing

A NA study of Cancer and Cardiovascular Disease, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
645
Enrollment target
1
Study location

NCT01969370: Completed NA study of Cancer and Cardiovascular Disease, sponsored by University of North Carolina, Chapel Hill.

NCT01969370 is a NA study of Cancer and Cardiovascular Disease that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 645 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01969370, a NA study of Cancer and Cardiovascular Disease, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
645 participants
Enrollment target
1
Study location

Study Summary

This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. This sub-project is investigating benefits and harms of providing WES diagnostic and different types of incidental findings to adult patients and parents of pediatric patients who undergo WES because they have symptoms suggesting genetic disease.

Primary Outcome

Measured with an adapted version of the multidimensional impact of testing scale (MICRA)

Interventions

  • BEHAVIORAL Experimental

Study Locations (1)

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 645 participants
Start Date 2012-08
Est. Completion 2017-03-01
Phase NA

What the finished NCT01969370 record still lists

NCT01969370 is an interventional study that assigns participants to a tested intervention. The registered 645 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (82% lower).

The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Experimental is the first listed.

NCT01969370 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT01969370 about?

NCT01969370 is a clinical study titled "NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing". This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. This sub-project is investigating benefits and harms of providing WES diagnostic and different types of incidental...

What is the current status of trial NCT01969370?

This trial is currently completed. It is a NA study. The enrollment target is 645 participants. The study started on 2012-08. Estimated completion is 2017-03-01.

What conditions does trial NCT01969370 study?

This clinical trial studies the following conditions: Cancer, Cardiovascular Disease, Hearing Loss, Congenital Abnormalities, Neurologic Dysfunction.

What interventions are being tested in trial NCT01969370?

The interventions under investigation include: Experimental (BEHAVIORAL).

Who is sponsoring clinical trial NCT01969370?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01969370 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01969370's enrollment target sits among peer trials

645 109th of 615 higher than 507 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07012395 · 645 participants · Phase 2

    A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  • NCT04863222 · 646 participants · Phase 4

    Clinical and Radiographic Success of MTA vs Biodentine

  • NCT05146297 · 644 participants · NA

    Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

  • NCT06994442 · 644 participants · Phase 3

    Optimizing Pain Treatment in Children On Mechanical Ventilation

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01969370, the US trial registry maintained by the National Library of Medicine. NCT01969370 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.